Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type

Erlotinib is one of the treatment choices for patients with advanced non-small cell lung cancer (NSCLC), regardless of the epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of patients with NSCLC with EGFR wild type or who are beyond the usage of gefiti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Hirai, Fumihiko, Edagawa, Makoto, Shimamatsu, Shinichiro, Toyozawa, Ryo, Toyokawa, Gouji, Nosaki, Kaname, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro, Ichinose, Yukito
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494899/
https://ncbi.nlm.nih.gov/pubmed/28693169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6118
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars